3.png
3.png

Sermorelin

$325.00

Sermorelin is a peptide that stimulates the body to produce more natural growth hormone, potentially supporting recovery, increased energy, and enhanced cellular repair.

Duration:

Sermorelin is a peptide that stimulates the body to produce more natural growth hormone, potentially supporting recovery, increased energy, and enhanced cellular repair.

Supply Duration: 9mg Vial. 63-105-day Supply - Dosage varies based on Male/Female*

Standard Dosing Protocol: Female: 100mcg | Male 200mcg subcutaneously, five days per week (5 days on 2 days off) This is standard protocol. The provider has the ability to change protocol based on their medical expertise.

What’s Included:

  • 63 Day Supply for Males or 105 Day Supply for Females (9 mg vial)

  • Medical Expertise & Guidance

  • Prescription grade, from a U.S. Licensed Compound Pharmacy

  • Reconstituted and ready-to-use

  • Syringes, supplies and instructions included

  • Free Expedited Shipping

Sermorelin is commonly explored for:

  • Recovery & tissue repair

  • Sleep quality

  • Metabolic & body composition support

  • Healthy aging & resilience

Common side effects

  • Injection site reactions (redness, swelling) Flushing at injection site Headache (usually mild and transient) Dizziness (rare) Nausea (uncommon)

  • Flushing at injection site

  • Headache (usually mild and transient)

  • Dizziness (rare)

  • Nausea (uncommon)

Contraindications and exclusions

  • Known allergy or hypersensitivity to Sermorelin or components

  • Active cancer (especially GH-sensitive tumors like breast, prostate, pituitary)

  • Pituitary tumors or history of pituitary disease

  • Diabetes or insulin resistance (monitor blood glucose)

  • Pregnancy and breastfeeding (not studied in these populations)

  • Thyroid dysfunction (may unmask hypothyroidism)

  • Sleep apnea (may worsen fluid retention)

Clinical & Research References for Sermorelin

  • Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. PubMed. https://pubmed.ncbi.nlm.nih.gov/18031173/ 

  • Wilton P, et al. GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy men (IV vs intranasal; GH response). PubMed. https://pubmed.ncbi.nlm.nih.gov/8329825/ 

  • Vance ML, et al. IV, subcutaneous, and intranasal GH-RH analog [Nle27]GHRH(1-29)-NH2 in normal men: dose-response relationships. PubMed. https://pubmed.ncbi.nlm.nih.gov/3096623/ 

  • Khorram O, et al. Nightly administration of a GHRH analog for 4 months in age-advanced men and women activates the somatotropic axis (body composition/skin outcomes reported). PubMed. https://pubmed.ncbi.nlm.nih.gov/9141536/